All In Biotech

Drug Trial Radar · NCT06947993

Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis

A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase II Platform Study to Assess the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis

Last checked: Nov 19, 2026Latest source record: Sep 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 224 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

224

Planned (sponsor's estimate)

Start

May 16, 2025

Primary completion

Nov 27, 2028

Study completion Dec 22, 2028

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Apr 27, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 100 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This trial is designed to evaluate multiple compounds in participants with moderate to severe atopic dermatitis (AD).

Conditions

  • Atopic Dermatitis

Interventions

  • GHZ339Drug

    GHZ339 administered at dose A, B, C and D

  • PlaceboDrug

    Matching placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline in the Eczema Area and Severity Index (EASI) score at Week 16Time frame: Baseline, Week 16

Locations

105 sites in 17 countries. Site status is shown where the registry gives one.

  • Novartis Investigative Site

    Birmingham, Alabama · Recruiting

  • Novartis Investigative Site

    Birmingham, Alabama · Recruiting

  • Novartis Investigative Site

    Fort Smith, Arkansas · Recruiting

  • Novartis Investigative Site

    Fountain Valley, California · Recruiting

  • Novartis Investigative Site

    Los Angeles, California · Recruiting

  • Novartis Investigative Site

    Sacramento, California · Recruiting

  • Novartis Investigative Site

    Santa Ana, California · Recruiting

  • Novartis Investigative Site

    Santa Monica, California · Recruiting

  • Novartis Investigative Site

    Washington D.C., District of Columbia · Recruiting

  • Novartis Investigative Site

    Miami, Florida · Recruiting

  • Novartis Investigative Site

    St. Petersburg, Florida · Recruiting

  • Novartis Investigative Site

    Atlanta, Georgia · Recruiting

  • Novartis Investigative Site

    Macon, Georgia · Recruiting

  • Novartis Investigative Site

    Louisville, Kentucky · Recruiting

  • Novartis Investigative Site

    Brighton, Massachusetts · Recruiting

  • Novartis Investigative Site

    Troy, Michigan · Recruiting

  • Novartis Investigative Site

    Saint Joseph, Missouri · Recruiting

  • Novartis Investigative Site

    Portsmouth, New Hampshire · Recruiting

  • Novartis Investigative Site

    Brooklyn, New York · Recruiting

  • Novartis Investigative Site

    Arlington, Texas · Recruiting

  • Novartis Investigative Site

    Cypress, Texas · Recruiting

  • Novartis Investigative Site

    Dallas, Texas · Recruiting

  • Novartis Investigative Site

    Houston, Texas · Recruiting

  • Novartis Investigative Site

    San Antonio, Texas · Recruiting

  • Novartis Investigative Site

    Caba, Buenos Aires, Argentina · Recruiting

  • Novartis Investigative Site

    Caba, Buenos Aires, Argentina · Recruiting

  • Novartis Investigative Site

    Rosario, Santa Fe Province, Argentina · Recruiting

  • Novartis Investigative Site

    Edmonton, Alberta, Canada · Active not recruiting

  • Novartis Investigative Site

    Hamilton, Ontario, Canada · Recruiting

  • Novartis Investigative Site

    Markham, Ontario, Canada · Recruiting

  • Novartis Investigative Site

    Montreal, Quebec, Canada · Recruiting

  • Novartis Investigative Site

    Verdun, Quebec, Canada · Active not recruiting

  • Novartis Investigative Site

    Beijing, China · Withdrawn

  • Novartis Investigative Site

    Beijing, China · Active not recruiting

  • Novartis Investigative Site

    Shanghai, China · Recruiting

  • Novartis Investigative Site

    Guangzhou, Guangdong, China · Active not recruiting

  • Novartis Investigative Site

    Shantou, Guangdong, China · Active not recruiting

  • Novartis Investigative Site

    Changsha, Hunan, China · Active not recruiting

  • Novartis Investigative Site

    Changchun, Jilin, China · Active not recruiting

  • Novartis Investigative Site

    Hangzhou, Zhejiang, China · Recruiting

Showing 40 of 105 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.